[CA 19-9 and CA 125 antigens in the sera of patients with cancer of the large intestine in relation to its clinical progress].
By radioimmunoassay the concentration of the CA 19-9 antigen was determined in the serum of 68 patients with large bowel cancer, while the CA 125 antigen was determined in 26 patients with this disease. Both markers were determined with CIS kits. In all, 127 determinations were done. The results were as follows: 1) CA 19-9 concentration increased with disease progression from 21% (in grade I of local-regional progression, A, B, C according to Dukes), through 41% above-normal results in group II (with metastases--Dukes' grade D), to 67% in case of recurrence of the tumor, and to 0% in group IV--with absent recurrence sign after radical surgical intervention. 2) CA 125 is without clinical value in large bowel cancer.
J
J
Bukowski
S
S
Góźdź
J
J
Słuszniak
W
W
Korejba
A
A
Zieliński
D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000097:blood*; D003110:Colonic Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor
Stezenie antygenu CA 19-9 i CA 125 w surowicy krwi chorych na raka jelita grubego w zalezności od zaawansowania klinicznego.